[COVID-19-associated coagulopathy]

Area of Science:

• Medical Research
• Infectious Diseases
• Cardiovascular Science

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, is linked to significant coagulopathy and thrombotic complications.
• The mechanisms underlying COVID-19-associated thrombosis are multifactorial, involving inflammation, endothelial dysfunction, and viral presence.
• Observed thrombotic events include arterial thrombosis, venous thromboembolism, and microthrombi in pulmonary capillaries.

Purpose of the Study:

• To elucidate the complex mechanisms of coagulopathy and thrombosis in COVID-19 patients.
• To highlight the necessity and limitations of prophylactic anticoagulant therapy in managing COVID-19-related thrombosis.
• To propose adjunctive therapeutic strategies for improving outcomes in COVID-19 patients with thrombotic complications.

Main Methods:

• Review and synthesis of current literature on COVID-19 pathophysiology, coagulopathy, and thrombosis.
• Analysis of clinical observations regarding thrombotic events in patients with varying COVID-19 severity.
• Evaluation of the efficacy of standard prophylactic anticoagulant therapies.

Main Results:

• COVID-19 involves a complex interplay of factors contributing to thrombosis, including immobility, coagulation activation, inflammation, and endothelialitis.
• Both arterial and venous thrombotic events, as well as pulmonary microthrombi, are prevalent in COVID-19.
• Standard prophylactic anticoagulant therapies demonstrate limited efficacy in fully preventing thrombosis in moderate to severe COVID-19 cases.

Conclusions:

• Prophylactic anticoagulant therapy is essential for moderate to severe COVID-19 but does not eliminate thrombotic risk.
• Combined strategies addressing underlying inflammation and protecting vascular endothelium are likely required alongside anticoagulation.
• Further research into comprehensive treatment approaches for COVID-19-associated coagulopathy and thrombosis is warranted.